


PHARMACEUTICAL 2023



Greenwich LifeSciences Inc. Rank 81 of 446





PHARMACEUTICAL 2023



Greenwich LifeSciences Inc. Rank 81 of 446



The relative strengths and weaknesses of Greenwich LifeSciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Greenwich LifeSciences Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 1,199% points. The greatest weakness of Greenwich LifeSciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 217%, being 174% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	9.0
Liabilities, Current	263
Liabilities, Non-Current	0
Other Assets	13,468
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	215
Other Revenues	0
Property and Equipment	0
Research and Development	6,476
Selling, General and Administrative Expense	1,565

Output Variable	Value in 1000 USD
Assets	13,477
Liabilities	263
Expenses	8,040
Revenues	0
Stockholders Equity	13,214
Net Income	-7,825
Comprehensive Net Income	-7,825
Economic Capital Ratio	217%

